Fast Five Quiz: Nail Psoriasis

William James, MD


October 24, 2021

Certain IL-23 inhibitors have similar efficacy to TNF-alpha inhibitors. For example, similar efficacy at week 24 has been noted with guselkumab and adalimumab. Adalimumab is the only biologic for which nail psoriasis efficacy data is included on the FDA label.

Comparative data are limited, but available head-to-head trials suggest that some biologics may be more efficacious than others for nail psoriasis. For example, brodalumab was shown to be more effective than ustekinumab at weeks 12, 24, 36, and 52. Ixekizumab has been shown to be more effective than guselkumab at week 24. IL-17 inhibitors have faster onset of action than TNF-alpha inhibitors, but long-term efficacy is similar.

For additional information, refer to the clinical practice guidelines on the management and treatment of psoriasis from the American Academy of Dermatology, the National Psoriasis Foundation, and the British Association of Dermatologists.

Learn more about systemic therapies and biologic agents for nail psoriasis.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: